Colorectal cancer (CRC) screening remains one of the most effective tools in preventive medicine. Yet even with multiple validated screening modalities and decades of clinical data, challenges persist. While overall CRC incidence has declined among older adults, rates are increasing in younger populations, and screening adherence remains inconsistent across demographic groups. For gastroenterologists, the conversation has evolved beyond simply expanding access. The imperative now is to right-size screening by aligning the right modality with the right patient at the right time, while ensuring outreach strategies meaningfully improve participation.
Right-sizing begins with thoughtful risk stratification. Average-risk screening starting at age 45 is now standard, but clinical decision-making must go deeper. Patients with a family history of CRC, hereditary syndromes, inflammatory bowel disease, or prior advanced neoplasia require individualized surveillance strategies. While these are risk factors that we understand, it is those that lack traditional risk factors that concern me the most. These are the patients that we are not currently identifying. To address the increasing prevalence of colon cancer in younger populations, we must leverage AI-driven predictive modeling. This approach allows for precise risk stratification, facilitating early intervention for non-traditional candidates who fall outside standard guidelines. This early intervention will need to be multi-modal. Overutilization of colonoscopy strains resources and exposes patients to unnecessary risk, while underutilization compromises early detection. Integrating accurate documentation, clear interval recommendations, and coordinated follow-up systems helps maintain both efficiency and safety.
At the procedural level, innovation continues to enhance detection. Computer-aided polyp detection systems now offer real-time prompts to identify subtle lesions that may otherwise be overlooked. Significant data now suggest these tools improve adenoma detection rates and reduce variability among endoscopists. Moreover, they may likely improve sessile serrated polyp detection rate which in the future will likely become the benchmark metric. Future iterations will not only assist in polyp detection but will also provide real time data on lesion size and inform the endoscopist on best removal practices. The goal of artificial intelligence in endoscopy is not just automation, but also consistency and quality reinforcement.
Noninvasive screening modalities also have a meaningful role in right-sizing care. As I mentioned earlier, I truly believe we need AI-driven algorithms to identify at risk patients under the age of 40. When this era comes, we will need multi-modal screening. Currently stool-based testing, including fecal immunochemical testing (FIT) and multitarget stool DNA and RNA assays, provides effective options for average-risk patients who are hesitant to undergo colonoscopy. In the future, I believe we will see these noninvasive CRC screening tests being used for the underage at risk population to identify those who need a colonoscopy prior to age 45. It is imperative to reinforce that screening does not end with a positive result on a noninvasive CRC screening test. Systems must ensure timely diagnostic colonoscopy after abnormal stool-based tests. Gaps in follow-up undermine the mortality benefit of screening and represent a critical operational vulnerability. Seamless coordination between primary care and gastroenterology practices is essential to preserve the integrity of the screening continuum. The goal has to be not only early detection, but early detection followed by early removal. This can only be done by a colonoscopy.
Outreach strategies are equally important. Disparities in CRC screening persist across racial, socioeconomic, and geographic lines. Traditional reminder-based approaches may not sufficiently address structural barriers such as transportation, health literacy, insurance complexity, and language differences. Patient navigation programs, culturally tailored education materials, digital engagement platforms, and employer-based health initiatives are demonstrating measurable improvements in screening completion. Data-driven outreach that identifies unscreened populations and deploys targeted interventions can meaningfully close care gaps.
Capacity and resource stewardship must also be considered. As screening eligibility expands and early-onset CRC receives increasing attention, demand for endoscopic services may grow. Optimizing open-access models, refining referral criteria, and adhering to evidence-based surveillance intervals can help balance procedural volume with quality standards. Metrics such as adenoma detection rate, sessile serrated detection rate, cecal intubation rate, withdrawal time, and appropriate surveillance recommendations remain central to delivering high-value care.
Right-sizing colorectal cancer screening is ultimately about precision and accountability. It requires leveraging technological advances without losing sight of clinical judgment. It demands expanding access while maintaining rigorous quality benchmarks. Most importantly, it calls for a coordinated approach that integrates detection, follow-up, and outreach into a cohesive strategy.
The next chapter in CRC prevention will not hinge solely on new tools. It will depend on how effectively we align innovation with equitable access and evidence-based practice to ensure screening is not only available but optimized for every patient we serve.
Author
Neil Parikh, MD, from Connecticut GI, a GI Alliance practice.